Article PDF first page preview

First page of Long-term trends in the burden of migraine in China: A comprehensive analysis from 1990 to 2021 and projections to 2035

Introduction Migraine is a widespread neurological disorder that significantly affects quality of life. Yet data on its burden in China remain limited. This study analyzes long-term trends (1990-2021) and projects future patterns. Methods Using Global Burden of Disease (GBD) 2021 database, we examined migraine incidence, prevalence, and disability-adjusted life years (DALYs). Temporal trends were assessed via joinpoint regression, while age-period-cohort (APC) analysis and decomposition analyses identified key influences. Bayesian APC modeling projected future trends through 2035. Results Migraine imposes a substantial health burden in China, with an annual incidence of 13.04 million cases, a prevalence of 184.75 million cases, and 6.98 million DALYs cases. Female is disproportionately affected, with peak prevalence occurs in the 30-49 age group. Individuals born post-1960 show increased susceptibility, like linked to demographic and lifestyle shifts. Population growth is a major driver of rising prevalence, with projections indicating a continued increase through 2035. Conclusion Migraine remains a significant public health concern in China, particularly among women. Targeted prevention, early detection, and intervention strategies are essential to mitigate its growing burden.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.